The Ledger / Seo Jung-jin
Seo Jung-jin
◼ Origin
Co-founded Celltrion in 2002 and took it public in 2008; built South Korea's largest biopharmaceutical company specializing in biosimilar drugs (Remsima, Herzuma) for cancer and inflammatory diseases. Returned as chairman in 2023 after stepping down in 2021.
◼ Self-Made Verdict — YES
Co-founded Celltrion in 2002 from scratch after a career at Samsung; built South Korea's leading biosimilar company through operational execution.
◼ Documented marks
01
Co-founded Celltrion in 2002 and pioneered South Korea's biosimilar pharmaceutical industry; Celltrion's Remsima (infliximab biosimilar) was the first biosimilar approved in both the EU and US, disrupting the $20B+ anti-TNF drug market.
02
South Korean prosecutors investigated Seo Jung-jin for alleged stock price manipulation related to Celltrion shares in multiple instances; regulatory scrutiny of his trading around biosimilar approval announcements has been documented by the Korean Financial Supervisory Service.
03
Stepped down as Celltrion chairman in 2021 before returning in 2023, pledging major acquisitions; the revolving leadership structure has raised corporate governance concerns among minority shareholders.
No inheritance, or primary accounts documented for this billionaire yet.
◼ List of charges
No documented charges yet.
These are moral charges, not legal ones. The actual legal system has not — and will not — bring them.
More ledger entries